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Abstract
Purpose: An artificial site for cell or pancreatic islet transplantation can be created using a
polymeric scaffold, even though it suffers subcutaneously from improper vascularisation. A
sufficient blood supply is crucial for graft survival and function and can be enhanced by
transplantation of mesenchymal stem cells (MSCs). The purpose of this study was to assess the
effect of syngeneic MSCs on neoangiogenesis and cell engraftment in an artificial site by
multimodal imaging.
Procedures: MSCs expressing a gene for luciferase were injected into the artificial subcutane-
ous site 7 days after scaffold implantation. MRI experiments (anatomical and dynamic contrast-
enhanced images) were performed on a 4.7-T scanner using gradient echo sequences.
Bioluminescent images were acquired on an IVIS Lumina optical imager. Longitudinal
examination was performed for 2 months, and one animal was monitored for 16 months.
Results: We confirmed the long-term presence (lasting more than 16 months) of viable donor
cells inside the scaffolds using bioluminescence imaging with an optical signal peak appearing
on day 3 after MSC implantation. When compared to controls, the tissue perfusion and vessel
permeability in the scaffolds were significantly improved at the site with MSCs with a maximal
peak on day 9 after MSC transplantation.
Conclusions: Our data suggest that the maximal signal obtained by bioluminescence and
magnetic resonance imaging from an artificially created site between 3 and 9 days after MSC
transplantation can predict the optimal time range for subsequent cellular or tissue transplan-
tation, including pancreatic islets.
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Introduction
Cellular replacement therapy has become a promising
therapeutic option for a variety of diseases, including type
1 diabetes mellitus. Intrahepatic implantation of donor
pancreatic islets (PIs) can restore normal insulin levels and
prevent hypoglycaemic episodes [1, 2], although the efficacy
and longevity of the procedure are not optimal. There are
various limitations to intraportal islet transplantation, e.g.,
reduction of immediate islet engraftment as well as long-
term function. Other factors include non-specific inflamma-
tion [3], liver ischaemia [4], thrombosis [5], permanent
hypoxia, significant excursion of nutrients, drugs and toxins
in the portal vein blood and/or technically impractical graft
biopsies. Therefore, an alternative transplantation
site—capable of providing an adequate vascular network
and minimally invasive access without any direct contact
with blood—is currently needed [6].
Anartificial sitecreatedusingapolymericscaffold inserted into
thegreateromentumorsubcutaneouslyhasalreadybeenproposed
as a suitable site for PI transplantation [7]. The advantages of
subcutaneous implantation are as follows: minimally invasive
surgery and the possibility to easily monitor islets. However, the
subcutaneous vascular network is inadequate and needs to be
enhanced for successful engraftment [8–10]. Pancreatic islets are
sensitive to hypoxia, which is even emphasised in environments
with high concentrations of glucose typical of a diabetic recipient.
Vascularisation of artificial devices can be enhanced by growth
factors, such as vascular endothelial growth factor (VEGF)
released in close vicinity to implanted scaffolds [11]. Mesenchy-
mal stem cells (MSCs) secrete various immunomodulatory, anti-
inflammatory and trophic factors, includingVEGF [12, 13]. It has
already been shown that MSCs can enhance angiogenesis both
in vitro [14] and in vivo [15, 16]. Several studies have shown
improved transplantation outcomes after co-transplantation of
pancreatic islets with MSCs due to improved graft
revascularisation [17, 18] and suppression of immune and
inflammatory responses [19,20].Moreover,MSCscanbe isolated
from the stromal vascular fraction of adipose tissue [21, 22];
therefore, they represent an available and easily reachable source
for potential clinical applications. Several pre-clinical studies have
illustrated the contribution of adipose-derived MSCs to neovas-
cularisation after ischaemic damage [23, 24].
In our group’s previous work, the experiments with
dynamic contrast-enhanced (DCE) magnetic resonance
imaging (MRI) showed that blood supply benefits from
MSC transplantation [8]. However, the long-term effect of
MSCs has not been examined yet. For this purpose, we used
genetically modified MSCs with expression of a luciferase
gene isolated from transgenic Lewis rats [25], which could
be tracked specifically over the long term by biolumines-
cence imaging (BLI). A luciferase reaction produces light,
which is dependent on the supply of oxygen and adenosine
triphosphate. Therefore, only viable cells can be visualised.
BLI has previously been used for monitoring the localisation
and fate of transplanted MSCs [26] and pancreatic islets [27]
in experimental models. Moreover, multimodal imaging of
the transplanted graft combining complementary BLI and
MRI methods can elucidate the local effect of viable MSCs
on the vascularisation level.
The goal of this study was to examine the long-term
influence of syngeneic adipose-derived MSCs on the blood
supply in subcutaneously implanted artificial devices using
multimodal imaging. Data relating to the level of vascular-
isation (obtained by imaging methods) were compared to
microvascular density analysis using immunohistology
slides. Based on the obtained findings, we here propose an
optimal transplantation timing schedule for pancreatic islets.
Materials and Methods
Animal Model
In this study, geneticallymodified Lewis rats with ubiquital expression of
a gene for the luciferase enzyme were used as donors of mesenchymal
stem cells (Lew-Tg(Gt(ROSA)26Sor-luc)11Jmsk,National BioResource
Project – Rat, Kyoto, Japan). Isolated cells were transplanted into the
cavity created using a polymeric macroporous scaffold shaped from a
non-degradable Silon monofilament mesh of 0.3 mm fibre diameter
(ELLA-CS, Czech Republic) (Fig. 1a). Two scaffolds were implanted
into the skin in the abdominal region of the male Lewis rats (250–300 g;
Velaz, Czech Republic; n = 6) under general anaesthesia (ketamine
60 mg/kg, dexmedetomidine 0.25 mg/kg) (Fig. 1b). Total obliteration of
the devices was prevented using a Teflon rod (Fig. 1a) inserted during the
first week. One week after the implantation, the rods from both devices
were removed and the cavities were tightly closed using 7-0 Mersilk
sutures (Ethicon, Johnson & Johnson Medical Ltd., Scotland). Immedi-
ately after, 15-mil ofMSCs in suspensionwas injected into the left cavity
using a 30-G needle syringe injection (Fig. 1c). A second device served
as a control without any transplanted cells. The design of the experiment
is shown in Fig. 1d.
All animals were kept in a conventional breeding facility under
a 12/12 light cycle regimen, with free access to pelleted food and
water in accordance with the European Convention of Animal Care
and the Animal Care Committee of the Institute for Clinical and
Experimental Medicine. The Ministry of Health of the
Czech Republic also approved the protocols related to this study.
Stem Cell Preparation
MSCs were isolated from the visceral adipose tissue of donor rats.
The fat tissue from the epididymal and perirenal area was carefully
excised, washed twice with cold phosphate-buffered saline and
centrifuged (500g, 5 min) after each wash. The rinsed tissue was
digested by collagenase (Sevapharma, 1340 PZS/g, 1 mg/ml;
Czech Republic) for 30 min at 37 °C. Digestion was terminated
upon the addition of ice-cold fetal bovine serum (Sigma-Aldrich,
USA), and the mixture was filtered through a 230-μm nylon mesh.
The suspension was then centrifuged and washed three times in
PBS with Euro-Collins solution (1000g; 10, 10 and 5 min). The
tissue pellet was then overlaid with 5 ml of PBS with Euro-Collins
solution and Ficoll solution (1077 g/ml, Ficoll-Paque™ Premium,
GE Healthcare Bio Science AB, Sweden). The cells in the
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interlayer were collected, washed with PBS and seeded in a tissue
culture flask (45 ml volume, 180 cm2 surface) with a DMEM low-
glucose medium, 10 % fetal bovine serum, 5 % HEPES and 1 % L-
glutamine-penicillin-streptomycin solution (Sigma-Aldrich, USA).
The culture medium was replaced twice a week, and the cells were
subcultured for 2 weeks after isolation. At this point, cells were
released from the bottom of the culture flask using trypsin,
dissolved in cold PBS, quantified and placed in the syringe before
the transplantation. One aliquot from each set of MSCs was
examined by fluorescent-activated cell sorting (FACS) in order to
identify adherent cells. Ten thousand cells were stained with the
following antibodies: anti-mouse endoglin/CD 105 (R&D Systems,
USA), anti-mouse/rat CD29 (BioLegend, USA), phycoerythrin/
CD44 (Abcam, UK), PE-Cy™5 Mouse Anti-Rat CD45 (BD
Biosciences, USA) and anti-rat/mouse CD90.1 Thy-1.1, Thy-1.1.
(E-Bioscience, USA) and were incubated for 20 min. The cells
were then washed with FACS solution (PBS, 0.2 % fish skin
gelatin, 0.01 % sodium azide) and analysed by flow cytometry (BD
FACSCalibur, BD Biosciences, USA). The data were analysed
using FlowJo 9.6.4 software (Tree Star, Inc., USA).
Magnetic Resonance Imaging
MRIexaminationwasperformedona4.7-TMRscanner(BrukerBioSpec,
Germany) using a resonator coilwith an internal diameter of 7 cm (Bruker
BioSpec, Germany). For anatomical localisation of the devices, conven-
tional anatomical images were acquired using a gradient echo sequence
(repetition of time (TR) = 88 ms, echo time (TE) = 3.7 ms, number of
acquisition (NA) = 12, acquisition time = 8 min). For dynamic
measurements, a three-dimensional gradient echo sequencewasusedwith
the following parameters: TR = 10 ms, TE = 3.1 ms, ma-
trix = 256 × 128 pixels, resolution = 0.2 × 0.4 × 0.7 mm3, evolution
delay=5s,32 slices,NA=1,24cycles andacquisition time=16min.The
temporal resolution of 1 cycle was 40 s. After the 8th cycle, the vascular-
specificMRcontrastagentGadofosveset (0.05mmol/kg)was injectedinto
the tailvein throughacatheter, avoiding thechange inanimalposition.The
data were processed using ImageJ software (version 1.46r, National
Institutes of Health, USA). The slices containing both the kidney and the
devices were evaluated. Regions of interest (ROIs) were outlined around
the kidney and around the internal diameter of each device (Fig. 2d). The
average signal intensity before injection of the contrast agent was
considered as the basal level (cycles 2–8), and the mean signal intensity
afteradministrationof thecontrastagent(cycles11–24)wasassessedasthe
contrast-enhanced level (Fig. 2a–c). The difference between basal- and
contrast-enhanced signal intensity normalised to the kidney signal was
calculated for every cycle of the ROI and expressed as amean percentage
enhancement.DCE-MRI experimentswere performed 7 and1 daybefore
MSC implantation and then on days 1, 3, 5, 7, 9, 11, 14, 22, 29, 37, 42, 50
and 56 afterMSC transplantation.
Optical Imaging
Optical images were acquired on an IVIS Lumina XR imager
(PerkinElmer, USA) with an exposure time of 1 min, an open
aperture and an open emission filter. A photographic image was
acquired for anatomical co-registration of the signal. Luciferase
expression of each set of cells was confirmed using BLI. Isolated
MSCs (0.6 × 105 − 1 × 106) were placed into a six-well plate and
imaged for 1 min after the addition of 10 μl of D-luciferin (30 mg/
ml). The MSC recipients were examined before and after
intravenous administration of D-luciferin dissolved in sterile PBS
(at a dose of 15 mg) in a time series lasting 14 min. The
bioluminescent colour-coded images were superimposed on the
photographic images and analysed using the Living Image software
package (PerkinElmer, USA). Signal intensity was assessed as
photons per second per square centimetre per steradian (p/s/cm2/sr)
from the area containing the scaffold. The area under the curve
(AUC) was calculated from each time course in order to minimise
the variability in D-luciferin administration among the measure-
ments. The bioluminescence examination was performed at the
same time points as the MRI experiments; one animal was
monitored for 16 months.
Fig. 1. Experiment design. a A photograph showing a device consisting of a macroporous monofilament scaffold combined
with a rounded Teflon rod. b A photograph showing the implantation procedure of the scaffold into the subcutaneous space in
the abdominal site of the animal and injection of MSCs into the artificial site through the skin and c engrafted scaffold. d A
schematic illustration of the design of the experiment.
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Histology and Immunohistochemistry
At the end of the experiment (56 days after MSC implantation, five
animals; 16 months, one animal), all transplant devices were
excised from the animals, fixed overnight in 10 % buffered
formalin (pH 7.4) at 4 °C and embedded in paraffin blocks. Serial
sections (4 μm) were cut and stained with haematoxylin and eosin
(H&E), Masson’s trichrome and elastic van Gieson stain.
Immunohistochemical detection of CD31 (rabbit polyclonal, Acris
Antibodies GmbH, Germany) was performed on 4-μm-thick paraffin
sections using a three-step indirect method. After deparaffinisation in
xylene and rehydration in graded ethanol, antigen retrieval (EDTA
buffer, pH 8), endogenous peroxidase and endogenous biotin blocking,
sections were covered with normal goat serum (Vector Laboratories,
USA) for 20 min. Primary antibody anti-CD31 was applied overnight at
4 °C; the antibody was detected by biotinylated goat anti-rabbit IgG
(H+L) (Vector Laboratories, Burlingame, CA, USA), and then the
sections were incubated with R.T.U. Vectastain Elite ABC Reagent
(Vector Laboratories, USA) for 30 min. Finally, visualisation was
performed with the Dako Liquid DAB+ Substrate-Chromogen System
(Dako, Denmark) and counterstaining with Harris’ haematoxylin.
Each slide was viewed using standard light microscopy
(Olympus BX41).
Microvascular Density Assessment
Microvascular density (MVD) assessment was performed at the end
of the 56-day experiment on two experimental and two control
samples. Two paraffin blocks were prepared from each sample;
three serial sections per block were stained with the primary anti-
CD31 antibody. MVD was evaluated in the area of the highest
vascularisation as a number of CD31-positive microvessels counted
at a magnification of ×400 (i.e., ×40 objective lens and ×10 ocular;
0.2375 mm2 per field). The results were expressed as the mean
microvessel count per ×400 view field. MVD was assessed by an
experienced pathologist.
Statistical Analysis
Statistical analysis was conducted using GraphPad Prism 6.02. The
average DCE-MRI signals of the control and experimental scaffolds
were compared per time point using two-tailed Student’s t test. The
significance level was set at p G 0.05.
Results
In Vitro Tests of MSCs
The isolated MSCs were analysed in vitro by flow cytometry
and bioluminescence imaging to confirm their typical
properties. A linear relationship between the number of the
isolated MSCs and bioluminescent signal was observed
(Fig. 3a, b). One million MSCs emitted 2.7 × 106 photons
per s from 1 cm2/steradian. Flow cytometry analysis
Fig. 2. DCE-MRI measurement. a The graph shows MR signal intensity changes before and after contrast agent (CA) injection.
Representative DCE-MR images b before and c after CA injection. d Region of interest in the artificial site chosen for
evaluation. EXP experimental scaffold with MSCs, CTRL control scaffold, K kidney.
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revealed CD45 negativity and thus the non-haematopoietic
origin of the tested cells. Moreover, the presence of the stem
cell-specific molecules on the cell surfaces was confirmed:
CD90 in 99.2 %, CD44 in 98.2 % and CD29 in 99.2 % of
the cells (Fig. 3c).
MRI and Bioluminescence Imaging
MRI examination showed that tissue surrounding the
Teflon rods engrafted the scaffolds within the first week
(Fig. 4a). The cavities inside the devices were visualised
by MRI after removal of the rod. The air bubbles were
detected on days 5 and 7 after MSC transplantation, after
which the cavities were filled with connective tissue
(Fig. 4b). The scaffolds with MSCs were engrafted and
filled with fibrous tissue faster compared to the controls.
The scaffold did not cause any imaging artifacts. No
difference in signal enhancement after the contrast agent
administration between the two scaffolds before MSC
implantation was observed, although there was a signif-
icant difference (p G 0.01) between days −7 and −1 (7
resp. 1 day before MSC implantation, Fig. 4c). Long-
term DCE-MRI examination revealed higher signal
enhancement in the devices with MSCs compared to
the control devices throughout the whole experiment
(Fig. 4d). The difference was significant on day 5
(p = 0.022), day 7 (p = 0.010), day 9 (p = 0.024), day
37 (p = 0.026), day 42 (p = 0.029) and day 56
(p = 0.022) after MSC implantation. The maximal
significant difference was observed on day 7, when
signal enhancement in the devices with MSCs reached
20.5 ± 4.3 and 11.2 ± 5.8 % in the control scaffolds.
The maximal signal enhancement on day 9 was
25.9 ± 3.4 % in the scaffolds with MSCs and
16.3 ± 5.5 in the control scaffolds. At the end of the
MRI experiment (day 56), perfusion and vessel perme-
ability in both scaffolds were higher than those in the
pre-transplant level with higher signal enhancement in
the scaffold with MSCs (13.2 ± 2.1 %) compared to the
control scaffold (9.8 ± 1.7 %).
Donor cells were visualised specifically inside the
scaffolds by bioluminescence imaging. No bioluminescent
signal was detected from the control scaffolds (Fig. 5a, c).
An optical signal, confirming the presence of the viable
donor cells, increased during the first 3 days after their
transplantation and then continuously declined (Fig. 5a, c).
A steep decrease in optical radiance was observed between
days 3 and 14 after donor cell transplantation, after which
the decrease slowed, resulting in a stable signal. After
2 months, the optical signal stayed at approximately 10–
15 % of the maximal signal level. The stable optical signal
was detected even 16 months after MSC implantation (one
animal) (Fig. 5c).
In summary, the optical signal peak appeared in advance
of maximal DCE-MRI signal. The optical signal reached its
maximal level on day 3, after which the perfusion and vessel
permeability inside the scaffolds with MSCs started to
elevate rapidly before reaching the maximal level on day
9. Based on these results, we propose that the optimal
transplantation window for implantation of pancreatic islet
ranges between days 3 and 9, as shown in Fig. 5b.
Fig. 3. Validation of stem cell characteristics. aIn vitro bioluminescent images of the isolated MSCs. b The linear relationship
between the optical signal and cell numbers in the in vitro experiment. c The presence of CD29- and CD44-specific molecules
on the MSC surface measured by FACS.
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Histological Evaluation of the Scaffolds
Histological analysis of the specimens showed both the
experimental scaffolds containing MSCs and controls
completely filled by sparse connective tissue composed
predominantly of collagen, extracellular matrix and cellular
component, including fibroblasts, macrophages and endo-
thelial cells (Fig. 6a, c). The immunohistochemical staining
with the anti-CD31 antibody highlighted the neovessels
within the devices (Fig. 6b, d, insets). Quantitative analysis
showed higher MVD in the experimental scaffolds with
MSCs compared to controls: the mean microvessel count per
×400 field was 17 ± 12 (median 14; range 2 to 40) in the
scaffolds with MSCs and 8 ± 3 (median 8; range 2 to 15) in
controls without MSCs.
Discussion
Non-degradable polymeric mesh can serve as a scaffold for
creation of an artificial transplantation site for cells or
pancreatic islets, although those implanted subcutaneously
suffer from insufficient vascularisation and associated
hypoxia [7]. The improvement of blood supply into
scaffolds after transplantation of mesenchymal stem cells
has already been demonstrated over a 4-week period, but the
long-term effect has only been predicted [8]. In the present
study, MSCs with luciferase expression were implemented
in order to assess the effect of MSCs on scaffold engraftment
in a longer period and in more detail using multimodal
imaging.
MR examination during the first week after scaffold
implantation revealed a cavity created by fibrous and
granulation tissue, which was suitable for subsequent
transplantation of MSCs. The absence of any difference in
DCE-MRI signal between the experimental and control
scaffolds before MCS transplantation confirmed the similar
condition in both sites at day 0. One week after the insertion
of MSCs, the scaffolds were fully filled by the tissue
enabling vessel growth throughout the whole scaffold
volume and thus providing an adequate environment for
the transplanted cells. Moreover, the layer of the fibrous
tissue was still thin enough to allow the oxygen to penetrate.
The survival of transplanted MSCs and/or cells differen-
tiated from them was monitored using detection of biolumi-
nescence signal generated by luciferase enzyme processing
of D-luciferin substrate. Bioluminescent MSCs and pancre-
atic islets have previously been transplanted and visualised
at different sites, such as the liver, kidney capsule [27], heart
[28] and under skin [29]. Our results showed that biolumi-
nescence imaging is a valuable strategy for tracking the
long-term fate of transplanted MSCs and their approximate
number in the artificial scaffolds. An advantage of the
method is that only viable cells are capable of producing
light and, therefore, being visualised [30]. However, the use
Fig. 4. MRI examination of the scaffolds before MSC transplantation. Representative anatomical MR images of the scaffolds a
before and b after MSC transplantation (Tx) acquired before administration of the contrast agent. MR signal enhancement
related to vascularisation in the scaffolds c before and d after Tx MSCs.
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of optical methods is limited by the attenuation of light
signal passing though the tissues [31]. In our model,
attenuation of the optical signal was minimised by subcuta-
neous transplantation of MSCs, which provided a robust and
stable optical signal. Moreover, a linear relationship between
the optical signal and the number of cells in vitro (Fig. 3)
together with an in vivo optical signal steady over a period of
more than 16 months post-implantation indicated a stable
expression for luciferase. During the first post-transplant
week, a strong optical signal was observed from the
transplanted MSCs gradually increased with the peak on
day 3. This reflected the maximal number of viable MSCs
and confirmed the adequate availability of oxygen and the
substrate D-luciferin for the luciferase reaction. Also,
neoangiogenesis as well as adaptation of MSCs in the host
may contribute to the gradual increase of the optical signal.
The ensuing progressive decline of the bioluminescent signal
during the second post-transplant week may reflect the
decrease in transplanted cell mass. These observations are in
accordance with previously reported gradual decrease in
bioluminescence signal during the first week after
transplantation of MSCs in a spinal cord injury model [32]
and in transplanted pancreatic islets [33]. The reduction of
isogeneic transplanted mass during the first 2 weeks was
previously documented in an animal study [34, 35] and also
in clinics [36]. The optical MSC signal decreased to
approximately 10–15 % of initial intensity after 21 days
and then remained stable until the end of the experiment (up
to 16 months), confirming the long-term viability of the
transplanted cells in the scaffolds and stable expression of
the gene for luciferase.
The real effect of MSCs on vascular network at the
transplantation site was confirmed by the dynamic contrast-
enhanced MRI, which was previously reported as a valuable
tool for estimation of vascularisation in a target region [9].
Changes in signal intensity after administration of the
contrast agent reflected extravasation of the contrast agent,
which is dependent on the number and density of the
vessels. In our study, the MR signal related to tissue
perfusion and vessel permeability significantly increased
over a one-week period after scaffold implantation, which
reflects ingrowth of the tissue together with increased
Fig. 5. Bioluminescence imaging of transplantedMCSs in the scaffolds and the suggested transplantation window. a A cumulative
optical signal originating from the devices at different time points after transplantation (Tx) of MSCs. b The relationship between the
MRI and BLI signal at different time points after MSC transplantation. c Representative in vivo optical images of the scaffolds with
bioluminescent MSCs. Arrow indicates control scaffold without any BLI signal. D day, M month, after MSC transplantation. b The
suggested transplantationwindow between day 3 (themaximal number of viableMSCs) and day 9 (themaximal perfusion and vessel
permeability) for further transplantation of pancreatic islets is expressed as a dashed rectangle.
Gálisová A. et al.: Multimodal Imaging of an Artificial Cell Transplant Site 21
vascularisation. The perfusion and vessel permeability in the
region of both scaffolds had rapidly increased over the first
9 days after MSC transplantation. This increase could be
related to the general reaction to the foreign body, which is
accompanied by the presence of macrophages, infiltration of
fibroblasts and neovascularisation in the new healing tissue
[37]. This process was observed and confirmed by the
histology in our model. The MSCs significantly enhanced
the local perfusion and vessel permeability in comparison to
controls throughout the whole examination period, which
reflects the positive effect of MSCs on vascularisation,
which can be caused by secretion of immunomodulatory and
vascular growth factors by MSCs [12, 16]. The highest
difference between the controls and scaffolds supported by
MSCs was observed between days 5 and 9 after MSC
transplantation. During this period, possible proliferation of
MSCs may also contribute to the increased production of
VEGF and thus increased neovascularisation. Enhancement
of neoangiogenesis has previously been monitored in animal
models [14]. Although optical imaging confirmed the long-
term viability of the transplanted cells, we cannot exclude
possible differentiation of MSCs into other cell types with
no substantial effect on vascularisation during later stages of
the experiment.
Our observation of long-term vascularisation improve-
ment in the scaffolds containing MSCs over at least a 2-
month period was confirmed histologically, as anti-CD31
staining for endothelial cells identified the markedly higher
formation of new vessels in the scaffolds with MSCs.
Increased microvascular density in the scaffolds with MSCs
compared to controls corresponded with the results obtained
by DCE-MRI. We may also speculate that the possible effect
of hypoxia early after MSC transplantation may induce
transcriptionally active hypoxia-inducible factors (HIFs),
which enhance the expression of VEGF, platelet-derived
growth factor (PDGF) and angiopoietin-2 [38, 39].
Taken together, the bioluminescence peak appearing on
day 3 and the maximal perfusion and vessel permeability
detected by DCE-MRI on day 9 after MSC implantation
suggest an optimal time window for subsequent transplan-
tation of pancreatic islets. Although previous studies have
shown lower blood supply in the subcutaneous scaffolds
compared to those implanted into the greater omentum [9],
we show that engraftment of MSCs and the optimal timing
could overcome this limitation.
Conclusion
We confirmed the positive effect of adipose tissue-derived
mesenchymal stem cells on vascularisation of the tissue at
the wall of the artificial transplantation site via increased
tissue perfusion and vessel permeability and higher micro-
vascular density. The long-term presence of viable cells of
donor origin inside the scaffolds observed by biolumines-
cence imaging supports this finding. Multimodal imaging
revealed the optimal timing for further cell implantation of
Fig. 6. Histology of the scaffolds. The experimental (a, b) and control (c, d) scaffolds are filled with the mesenchymal tissue.
Microvascular density is higher in the specimen with b MSCs compared to the d control. H&E staining (a–d), anti-CD31
immunohistochemistry (insets). Original magnifications ×100 (a, c) and ×400 (b, d, insets).
22 Gálisová A. et al.: Multimodal Imaging of an Artificial Cell Transplant Site
the scaffolds. Improved vascularisation, proper timing of the
transplantation steps and prolongation of cell survival due to
implantation of MSCs might ameliorate the efficacy of
transplantation outcomes in further applications.
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